Universitaetsklinikum Erlangen AöR
Verified site
Erlangen, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on adults with uncontrolled hypertension, a condition where blood pressure remains high despite usual treatment. Participants will receive either the oral medication vicadrostat, the oral medication empagliflozin, or a matching placebo that looks the same but contains no active drug. Both drugs are taken as a film‑coated tablet once daily. Blood pressure is the force of blood against the walls of the arteries, and the systolic number is the higher value measured when the heart beats.
The aim of the trial is to see whether the combination of vicadrostat and empagliflozin can lower the office systolic blood pressure after 12 weeks compared with placebo. After a short screening period, participants will attend regular clinic visits where the study medication is given, blood pressure measurements are taken, and simple tests of vascular structure and function are performed to assess how the blood vessels are working. The study lasts for about three months, with visits scheduled at the start, during the treatment period, and at the end to collect the final results.
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
3 criteria
24 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Erlangen, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an experimental oral tablet being tested to see if it can lower blood pressure and improve the health of blood vessels in people whose high blood pressure is not well controlled. In this study participants take the tablet once a day for twelve weeks, and researchers measure changes in their blood pressure and the way their blood vessels work.
(commercially known as Jardiance) is a pill that is usually used to help control blood sugar in diabetes, but it also has effects that can lower blood pressure. In this trial the drug is given to participants with uncontrolled hypertension to find out whether it can reduce the pressure in the arteries and improve the structure and function of the blood vessels over a twelve‑week period.
It is taken by mouth as a film‑coated tablet, 10 mg once daily. This compound is still experimental and has not been approved for any medical use. It is being studied for its ability to lower high blood pressure by helping blood vessels relax. It belongs to a class of investigational agents that target vascular tone.
It is taken by mouth as a film‑coated tablet, 10 mg once daily. Empagliflozin is an approved medicine for type 2 diabetes and is also used to reduce heart‑related risks. It works by blocking a kidney protein that re‑absorbs sugar, causing extra glucose and water to be excreted, which can help lower blood pressure. It is classified as an SGL‑2 inhibitor, a type of oral glucose‑lowering drug.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.